摘要
目的探讨ERCC1(C118T)、XRCC1(G399A)的单核苷酸多态性(SNP)与非小细胞肺癌(NSCLC)对铂类为主化疗方案敏感性的关系。方法经病理学确诊的晚期NSCLC患者120例,采用铂类为主的两药联合化疗方案,2～3个周期后进行临床疗效评价。根据cDNA芯片原理制作目的基因芯片,利用双色荧光探针杂交进行ERCC1、XRCC1的多态性的基因分型,比较不同基因型与化疗敏感性的关系。结果 ERCC1(C118T)至少携带1个T等位基因型的患者化疗有效率为44.7%,显著高于C/C基因型的19.2%(P<0.05);携带XRCC1(G399A)G/G基因型者化疗有效率为43.8%,高于至少携带1个A等位基因的19.4%(P<0.05)。结论 ERCC1、XRCC1基因多态性与NSCLC患者对铂类药物化疗的敏感性相关。
Objective To study the relationship of single nucleotide polymorphisms（SNP） and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer（NSCLC）.Methods A total of 120 patients with advanced NSCLC were routinely treated by cisplatin or carboplatin-based chemotherapy.The clinical response was evaluated after 2 to 3 cycles.The DNA repair gene ERCC1（C118T） and XRCC1（G399A） genotypes were determined by gene-chip method using DNA samples isolated from peripheral blood collected before treatment.Pearson Chi-square test was performed among variant genotypes.The odds ratios（OR） and 95% confidence intervals （CI） were computed by logistic regression.Results Homozygous wild type, heterozygote type and homozygous mutant type yielded green,yellow and red fluorescence, respectively.The response rate to the chemotherapy in patients with the ERCC1 118 C/T and T/T genotype was significantly higher than that in patients with the C/C （44.7% vs. 19.2%,OR=0.294,95% CI=0.130-0.666）（P0.05）.The response rate to the chemotherapy in the patients with the XRCC1 399 G/G genotype was significantly higher than that in the patients with the G/A and A/A （43.8% vs. 19.4%,OR=3.222,95% CI=1.425-7.287）（P0.05）.Conclusion Polymorphism of ERCC1 and XRCC1 gene may have a significant impact on the response of NSCLC patients to platinum-based chemotherapy.
出处
《江苏医药》
CAS
CSCD
北大核心
2011年第3期272-274,共3页
Jiangsu Medical Journal
基金
江苏省自然科学基金前期预研项目(BK2005203)
南京市医学科技发展重点项目基金(ZKX05030)
